Free Trial
ASX:IMU

Imugene (IMU) Stock Price, News & Analysis

Imugene logo

About Imugene Stock (ASX:IMU)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
12.70 million shs
Average Volume
N/A
Market Capitalization
$290.84 million
P/E Ratio
N/A
Dividend Yield
3.03%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Receive IMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imugene and its competitors with MarketBeat's FREE daily newsletter.

IMU Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Imugene secures CD19 oncolytic virus patent in China
See More Headlines

IMU Stock Analysis - Frequently Asked Questions

Imugene Limited (ASX:IMU) posted its earnings results on Thursday, February, 28th. The company reported $0.00 earnings per share for the quarter. Imugene had a negative net margin of 1,855.22% and a negative trailing twelve-month return on equity of 95.62%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imugene investors own include Meta Platforms (META), NVIDIA (NVDA), Precision BioSciences (DTIL), Fortescue (FMG), Teladoc Health (TDOC), Viralytics (VRACY) and Whitehaven Coal (WHC).

Company Calendar

Last Earnings
2/28/2019
Today
4/26/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
ASX:IMU
CIK
N/A
Fax
N/A
Employees
110
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-149,680,000.00
Net Margins
-1,855.22%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.97 million
Price / Cash Flow
3.75
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
7,570,000,000
Free Float
N/A
Market Cap
$290.84 million
Optionable
Not Optionable
Beta
3.34
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (ASX:IMU) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners